Europe Approves Empagliflozin for Chronic Kidney Disease Europe Approves Empagliflozin for Chronic Kidney Disease
The SGLT2 inhibitor empagliflozin (Jardiance) was approved by European regulators for treating adults with chronic kidney disease. The FDA is reviewing a new drug application for this indication.Medscape Medical News
Source: Medscape Internal Medicine Headlines - Category: Internal Medicine Tags: Diabetes & Endocrinology News Alert Source Type: news
More News: Chronic Kidney Disease | Diabetes | Empagliflozin | Endocrinology | Internal Medicine | Jardiance | New Drug Applications | SGLT2 Inhibitors | Urology & Nephrology